Table 1.
Characteristics of patients with relapsed/refractory diffuse large B-cell lymphoma (n = 55) treated with bendamustine–rituximab
| Variables | n (%) |
|---|---|
| Gender | |
| Male | 22 (40) |
| Female | 33 (60) |
| Age, years | |
| <65 | 22 (40) |
| ≥65 | 33 (60) |
| Clinical stage (Ann Arbor staging) | |
| I | 3 (5) |
| I-E | 2 (4) |
| II | 16 (29) |
| II-E | 2 (4) |
| III | 14 (25) |
| III-E | 4 (7) |
| III-S | 2 (4) |
| IV | 13 (24) |
| B symptoms | |
| Yes | 6 (11) |
| No | 49 (89) |
| Prior medication | |
| Yes | 50 (91) |
| No | 5 (9) |
| Prior ASCT | |
| Yes | 8 (15) |
| No | 47 (55) |
| No. of regimens | |
| 1 | 37 (67) |
| 2 | 12 (22) |
| 3 | 6 (11) |
| Performance status | |
| 0 | 37 (67) |
| 1 | 18 (33) |
| LDH, U/L | |
| <240 | 26 (47) |
| ≥240 | 29 (53) |
| Nodal sites | |
| <4 nodular sites | 51 (93) |
| ≥4 nodular sites | 4 (7) |
| Extranodal sites | |
| <2 extranodular sites | 26 (47) |
| ≥2 extranodular sites | 29 (53) |
| Bone marrow involvement | |
| Positive | 8 (15) |
| Negative | 47 (85) |
| IPI risk category | |
| Low | 20 (36) |
| Low–intermediate | 21 (38) |
| High–intermediate | 10 (18) |
| High | 4 (7) |
ASCT, autologous stem cell transplantation; IPI, International Prognostic Index; LDH, lactate dehydrogenase.